Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Fateme Sadri-Ardalani"'
Autor:
Fateme Sadri-Ardalani, Moslem Ahmadi, Azam Hemmati, Shaghayegh Emami, Samira Farid, Mohammad Mehdi Amiri, Mahmood Jeddi-Tehrani, Mahdi Shabani, Fazel Shokri
Publikováno v:
Iranian Journal of Immunology, Vol 14, Iss 2, Pp 99-110 (2017)
Background: In addition to passive immunotherapy using anti-HER2 monoclonal antibodies, active immunotherapy via HER2 targeting is an interesting approach to inducing specific anti-tumor immune responses. We have recently reported the immunogenicity
Externí odkaz:
https://doaj.org/article/c2164a5c397a40ed95a88bbf17905e99
Autor:
Fazel Shokri, Moslem Ahmadi, Mahdi Shabani, Mohammad Mehdi Amiri, Fateme Sadri-Ardalani, Mahmood Jeddi-Tehrani
Publikováno v:
Immunotherapy. 10:511-524
Aim: We investigated cellular and protective immune responses in mice vaccinated with recombinant HER2 extracellular subdomains. Materials & methods: Balb/C mice were immunized with recombinant full HER2 extracellular domain and subdomain proteins. H
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::86f7c220d05249ad09ab84a771ccc102
https://doi.org/10.2217/imt-2017-0181
https://doi.org/10.2217/imt-2017-0181
Autor:
Shaghayegh Emami, Fateme Sadri-Ardalani, Ali Reza Sarrafzadeh, Fazel Shokri, Mohammad Mehdi Amiri, Mahdi Shabani, Mahmood Jeddi-Tehrani, Motahareh Bahadori, Farzaneh Noutash-Haghighat
Publikováno v:
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 37(1)
Human epidermal growth factor receptor 2 (HER2) is overexpressed in 15-20 % of breast cancer patients and is an appropriate target for immunotherapy in these patients. Monoclonal antibodies (mAbs) specific to HER2 are currently applied to treat breas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6d1819c270bafba078351d81755f4d2c
https://pubmed.ncbi.nlm.nih.gov/26282003
https://pubmed.ncbi.nlm.nih.gov/26282003